OMCL Company Profile and Key Details

Q: Who are the executives of OMCL?

Mr. Giri ChodavarapuSenior Vice President & Chief Information OfficerMs. Kathleen NemethSenior Vice President of Investor RelationsMs. Christine MellonExecutive Vice President, Chief Admin. & People OfficerMs. Roxanne TurnerSenior Vice President of Corporation Responsibility and Chief Compliance & Privacy OfficerMr. Jorge R. TaborgaExecutive Vice President of Engineering & Integration Management OfficerMr. Virad GuptaSenior Vice President & Chief Technology OfficerMr. Joseph Brian SpearsSenior Vice President, Chief Accounting Officer & Corporation ControllerMr. Randall A. LippsFounder, Executive Chairman, Pres & Chief Executive OfficerMr. Scott Peter SeidelmannExecutive Vice President & Chief Commercial OfficerMr. Nchacha EttaExecutive Vice President & Chief Financial OfficerMs. Christine M. MellonExecutive Vice President & Chief Admin. OfficerMr. Corey J. ManleyExecutive Vice President and Chief Legal & Admin. OfficerMr. Peter J. KuipersExecutive AdviserMs. Minoo MortazaviSenior Vice President of Global OperationsMr. Maximo RochaSenior Vice President & Chief People Officer

NASDAQ : OMCL

Omnicell

$34.46

0.15+0.44%

At Close 4:00 PM

67.59

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Omnicell, Inc. (OMCL) stock surged +0.44%, trading at $34.46 on NASDAQ, up from the previous close of $34.31. The stock opened at $33.80, fluctuating between $33.38 and $34.76 in the recent session.

Stock Snapshot

34.31

Prev. Close

1.57B

Market Cap

33.375

Day Low

861.5

P/E Ratio

0.04

EPS (TTM)

2.77

Cash Flow per Share

33.8

Open

45.44M

Number of Shares

34.755

Day High

97.58%

Free Float in %

26.13

Book Value

306.43K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 24, 2026	33.80	34.76	33.38	34.46	341.58K
Mar 23, 2026	34.23	34.61	33.96	34.31	471.25K
Mar 20, 2026	33.43	33.60	32.19	33.09	1.09M
Mar 19, 2026	33.67	34.24	33.28	33.40	716.69K
Mar 18, 2026	34.56	34.85	33.90	34.03	494.28K
Mar 17, 2026	34.42	35.61	34.42	35.09	494.88K
Mar 16, 2026	34.69	35.20	34.19	34.29	564.5K
Mar 13, 2026	35.58	35.62	33.87	34.40	1.02M
Mar 12, 2026	36.89	37.15	34.85	35.10	886.1K
Mar 11, 2026	39.00	39.28	37.32	37.48	710.11K
Mar 10, 2026	39.83	40.18	38.96	38.99	445.81K
Mar 09, 2026	40.07	40.71	38.88	39.83	429.3K
Mar 06, 2026	41.01	42.15	40.67	41.30	855.03K
Mar 03, 2026	40.24	41.21	39.97	40.80	397.26K
Mar 02, 2026	40.13	41.31	40.07	41.25	634.58K
Feb 27, 2026	41.85	41.85	40.91	41.10	525.9K
Feb 26, 2026	41.55	42.60	40.84	41.93	712.59K
Feb 25, 2026	40.45	41.47	40.05	41.37	791.91K
Feb 24, 2026	39.62	40.74	39.56	40.15	583.03K
Feb 23, 2026	39.65	39.83	38.66	39.56	593.03K

Contact Details

Mountain View, CA 94043

United States

https://www.omnicell.com 650 251 6100

About Company

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Stock Peers

BTSGU

3.835+2.72%

BrightSpring Health Services, Inc. Tangible Equity Unit$144.79 NUTX

4.51+4.75%

Nutex Health, Inc.$99.49 HQY

0.46+0.56%

HealthEquity, Inc.$82.10 GEHC

-0.69-0.96%

GE HealthCare Technologies Inc.$70.96 WGS

-3.47-4.81%

GeneDx Holdings Corp.$68.67 TEM

-0.31-0.63%

Tempus AI, Inc.$48.83 BTSG

1.21+2.87%

BrightSpring Health Services, Inc. Common Stock$43.31 PINC

0.09+0.32%

Premier, Inc.$28.26 HTFL

1.15+4.29%

Heartflow, Inc. Common Stock$27.97 CCLDO

CareCloud, Inc.$26.18

Company Overview

Omnicell, Inc. (NASDAQ:OMCL) closed at $34.46 USD, gaining $0.15 (0.44%) from the previous close of $34.31. The stock is currently mid-range between its 52-week high and low $22.66 and $55.00. With a market capitalization of about $1.57 billion, Omnicell, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.79). Key stats such as the average daily volume over the past year has been around 655.28 thousand shares, volume is running light vs its 52-week average. Headquartered in Mountain View, CA, Omnicell, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Randall A. Lipps, the company employs approximately 3,620 people and listed since August 09, 2001. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 2.39%, SMA50 -7.23%, SMA200 19.53%). The stock’s 14-day RSI is 49.77 (neutral), while the ATR of 2.01 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.12% below its high and over 85.04% above its low. Average 10-day trading volume of 595.46 thousand shares is in line with the 3-month average of 636.45 thousand, indicating normal recent market interest.

Valuation Metrics

Omnicell, Inc. trades at a P/E ratio of 757.86, slightly above the S&P 500 average, with a price-to-sales ratio of 1.33 and a price-to-book ratio of 1.26 suggesting the stock is closer to book value. The P/FCF stands at 18.61, also above market averages.

Dividend & Fair Value

Omnicell, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $85.17. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Omnicell, Inc. generated EPS of $0.04 over the past year. Five-year average earnings growth is -43.0%. Wall Street analysts project EPS growth of 16.02% annually over the next five years. The latest quarter delivered EPS of $0.12. The next quarter is forecast at $0.33. Next year's EPS is expected at $0.54. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $40.00. The high target offers 74.11% upside. The low target suggests 16.08% downside. The mean target is $51.38. This offers 49.1% upside. Omnicell, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by -67.47%. The prior quarter beat by 45.16%. Over the last six quarters, Apple has recorded several small beats. These include -49.29% in August 01, 2024.

Shareholding & Insider Activity

Omnicell, Inc. has 45.93 million shares outstanding. The public float is 44.82 million shares, elevated short interest at 6.42% of float. This equals 2.04 million shares. The short ratio is 4.15 days. Institutional investors hold 107.65% of the float. Insiders own 1.79%. LIPPS RANDALL A holds 386.65 thousand shares, Manley Corey J has 96.72 thousand shares and Kuipers Peter J. has 61.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 55.86 thousand shares across 7 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Omnicell generated $1.15B in revenue, or $25.37 per share. Gross margin was 43.58%, operating margin -1.69%, and net profit margin -1.78%. Returns are negative, with ROA at -0.91% and ROE at -1.71%.
On valuation metrics, Omnicell trades at a P/E of 757.86, P/S of 1.33 and P/B of 1.26. The current ratio is 1.43 and quick ratio is 1.22. Operationally, the company’s inventory turnover is 6.75 and cash conversion cycle is 97.29 days. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of 0.62.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Omnicell posted revenue of $1.15B, down slightly from $1.30B in the prior quarter. Gross profit was $499.93M (margin 43.58%). Operating income was - $19.33M (margin -1.7%). Net income was- $20.37M (EPS - $0.45).
The company ended the quarter with $500.98M in cash and short-term investments, a total debt of $614.09M, and net debt of $113.11M. Total assets were $2.23B, with equity of $1.19B. Financials further reflected stability, with operating cash flow of $181.09M, free cash flow of $126.08M, and capital expenditures of - $55.02M.

Price Forecast & Outlook

Our AI price prediction model suggests that Omnicell, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.94%, with price expected at $31.38 by April 06, 2026, within a range of $27.49 to $35.18 3-Month Outlook: Projected rise of 46.6%, reaching $50.52 by June 19, 2026, with a range of $49.13 to $52.15. 1-Year Outlook: Projected loss of -10.33%, with price at $30.90 by March 23, 2027, within a range of $26.41 to $33.98.

Key Takeaways

Omnicell, Inc. (NASDAQ:OMCL) shares are flat 8.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Omnicell, Inc. trading at a premium to the broader market with a P/E of 757.86. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $72.78, suggesting 111.2% upside. Our AI forecast model points to short-term weakness (-8.94% over two weeks), a medium-term rise (46.6% over three months), and a longer-term loss (-10.33% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Omnicell, Inc. (OMCL) stock price?

Omnicell, Inc. (NASDAQ: OMCL) stock price is $34.46 in the last trading session. During the trading session, OMCL stock reached the peak price of $34.76 while $33.38 was the lowest point it dropped to. The percentage change in OMCL stock occurred in the recent session was 0.44% while the dollar amount for the price change in OMCL stock was $0.15.

OMCL's industry and sector of operation?

The NASDAQ listed OMCL is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector. Omnicell, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OMCL?

Mr. Giri Chodavarapu
Senior Vice President & Chief Information Officer
Ms. Kathleen Nemeth
Senior Vice President of Investor Relations
Ms. Christine Mellon
Executive Vice President, Chief Admin. & People Officer
Ms. Roxanne Turner
Senior Vice President of Corporation Responsibility and Chief Compliance & Privacy Officer
Mr. Jorge R. Taborga
Executive Vice President of Engineering & Integration Management Officer
Mr. Virad Gupta
Senior Vice President & Chief Technology Officer
Mr. Joseph Brian Spears
Senior Vice President, Chief Accounting Officer & Corporation Controller
Mr. Randall A. Lipps
Founder, Executive Chairman, Pres & Chief Executive Officer
Mr. Scott Peter Seidelmann
Executive Vice President & Chief Commercial Officer
Mr. Nchacha Etta
Executive Vice President & Chief Financial Officer
Ms. Christine M. Mellon
Executive Vice President & Chief Admin. Officer
Mr. Corey J. Manley
Executive Vice President and Chief Legal & Admin. Officer
Mr. Peter J. Kuipers
Executive Adviser
Ms. Minoo Mortazavi
Senior Vice President of Global Operations
Mr. Maximo Rocha
Senior Vice President & Chief People Officer

How OMCL did perform over past 52-week?

OMCL's closing price is 52.07% higher than its 52-week low of $22.66 where as its distance from 52-week high of $55.00 is -37.34%.

How many employees does OMCL have?

Number of OMCL employees currently stands at 3,620.

Link for OMCL official website?

Official Website of OMCL is: https://www.omnicell.com

How do I contact OMCL?

OMCL could be contacted at phone 650 251 6100 and can also be accessed through its website. OMCL operates from 590 East Middlefield Road, Mountain View, CA 94043, United States.

How many shares of OMCL are traded daily?

OMCL stock volume for the day was 306.43K shares. The average number of OMCL shares traded daily for last 3 months was 655.28K.

What is the market cap of OMCL currently?

The market value of OMCL currently stands at $1.57B with its latest stock price at $34.46 and 45.44M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	3620
Beta	0.79
Sales or Revenue	$1.15B
5Y Sales Change%	0.265%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Healthcare Information Services

OMCL Company Profile and Key Details

Omnicell

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook